BioMarin Pharmaceuticals BMRN Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Agios PharmaceuticalsAGIO

$572.7M-8.6%

BridgeBio PharmaBBIO

$42.25M—

Denali Therapeutics Inc.DNLI

$508.94M-39.1%

FAQ

What is BioMarin Pharmaceuticals's cash, cash equivalents, and marketable securities?

BioMarin Pharmaceuticals (BMRN) reported cash, cash equivalents, and marketable securities of $874.01M in Q2 2026.

How has BioMarin Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?

BioMarin Pharmaceuticals's cash, cash equivalents, and marketable securities decreased by 55.0% year-over-year, from $1.94B to $874.01M.

What is the long-term trend for BioMarin Pharmaceuticals's cash, cash equivalents, and marketable securities?

Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's cash, cash equivalents, and marketable securities has grown at a 8.7% compound annual growth rate (CAGR), from $1.35B to $2.05B.

What does cash, cash equivalents, and marketable securities mean?

This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.